The Watertown, Massachusetts-based biotech had been evaluating the CHK1/2 inhibitor, called prexasertib or ACR-368, in a phase 2b trial of patients with endometrial cancer. These patients were ...

Figure 2: PP2Cδ and the DNA-damage response. The discovery that a phospho-SQ motif in CHK1 is a substrate for PP2Cδ prompted a similar investigation of p53, which is itself an ATM/ATR substrate.

Analysts at Cantor Fitzgerald pointed out the lead asset, ACR-368, a CHK1/2 inhibitor, as a candidate for Accelerated Approval in endometrial cancer potentially as early as 2026. The optimism is ...

Research and Development Highlights and Upcoming Milestones BBI-355, a novel, oral, potent CHK1 inhibitor designed to target replication stress in oncogene-amplified cancers Enrollment in the ...